Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 30, Issue 7, 2011, Pages 895-901

  Pachon Ibanez M E ^a   Docobo Perez F ^a   Jimenez Mejias M E ^a   Ibanez Martinez J ^b   Garcia Curiel A ^a   Pichardo, C ^a   Pachon J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; IMIPENEM; RIFAMPICIN; SULBACTAM;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG HALF LIFE; EXPERIMENTAL MODEL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT DURATION;

ACINETOBACTER BAUMANNII; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; IMIPENEM; LUNG; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PNEUMONIA, BACTERIAL; RIFAMPIN; RODENT DISEASES; SULBACTAM; TREATMENT OUTCOME;

EID: 80051665146     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1173-6     Document Type: Article

References (31)

1. Rodríguez-Baño J, Cisneros JM, Fernández-Cuenca F; Grupo de Estudio de Infección Hospitalaria (GEIH) et al (2004) Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol 25:819-824 (Pubitemid 40036756)
2. Rodríguez-Baño J, García L, Ramírez E et al (2009) Long-term control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive "bundle" approach. Am J Infect Control 37:715-722
3. Michalopoulos A, Falagas ME (2010) Treatment of Acinetobacter infections. Expert Opin Pharmacother 11:779-788
4. McGowan JE Jr (2006) Resistance in nonfermenting gramnegative bacteria: multidrug resistance to the maximum. Am J Med 119(6 Suppl 1):S29-S36; discussion S62-S70 (Pubitemid 43776143)
5. Falagas ME, Kasiakou SK, Tsiodras S et al (2006) The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 4:138-146 (Pubitemid 44047368)
6. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ et al (2003) Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36:1111-1118 (Pubitemid 36549630)
7. De Pascale G, Pompucci A, Maviglia R et al (2010) Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intrathecal and intravenous colistin. Minerva Anestesiol 76:957-960
8. Valencia R, Arroyo LA, Conde M et al (2009) Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 30:257-263
9. Cisneros-Herreros JM, Garnacho-Montero J, Pachón- Ibáñez ME (2005) Nosocomial pneumonia due to Acinetobacter baumannii. Enferm Infecc Microbiol Clín 23(Suppl 3):46-51 (Pubitemid 47394842)
10. Li J, Nation RL, Owen RJ et al (2007) Antibiograms of multidrugresistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 45:594-598 (Pubitemid 47328640)
11. Ko KS, Suh JY, Kwon KT et al (2007) High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 60:1163-1167 (Pubitemid 47617772)
12. Montero A, Ariza J, Corbella X et al (2004) Antibiotic combinations for serious infections caused by carbapenemresistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 54:1085-1091 (Pubitemid 40136746)
13. Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R et al (2010) Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54:1165-1172
14. Vaneechoutte M, Dijkshoorn L, Tjernberg I et al (1995) Identification of Acinetobacter genomic species by amplified ribosomal DNA restriction analysis. J Clin Microbiol 33:11-15 (Pubitemid 24382389)
15. Clinical and Laboratory Standards Institute (CLSI) (2010) Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement. Document M100-S20. CLSI, Wayne, PA
16. Société Française de Microbiologie (SFM) (2010) Comite de l'antibiogramme de la Société Française de Microbiologie. SFM, Paris, France. Home page at: http://www.sfm-microbiologie. org/pages/?all=accueil, accessed August 11, 2010
17. National Committee for Clinical Laboratory Standards (NCCLS) (1999) Methods for determining bactericidal activity of antimicrobial agents: approved standard M26-A. NCCLS, Wayne, PA
18. Pillai SK, Moellering RC Jr, Eliopoulos GM (2005) Antimicrobial combinations. In: Lorian V (ed) Antibiotics in laboratory medicine, 5th edn. Lippincott Williams & Wilkins, Philadelphia, PA, pp 365-440
19. Klein RD, Edberg SC, Lorian V (2005) Applications, significance of, and methods for the measurement of antimicrobial concentrations in human body fluids. In: Lorian V (ed) Antibiotics in laboratory medicine, 5th edn. Lippincott Williams & Wilkins, Philadelphia, PA, pp 290-364
20. Rodríguez-Hernández MJ, Pachón J, Pichardo C et al (2000) Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother 45:493-501 (Pubitemid 30199143)
21. Amsden GW (2010) Table of antimicrobial agent pharmacology. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases, 7th edn. Churchill Livingstone Elsevier, Philadelphia, PA, pp 705-761
22. Ruslami R, Nijland HM, Alisjahbana B et al (2007) Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 51:2546-2551 (Pubitemid 47047335)
23. Wolff M, Joly-Guillou ML, Farinotti R et al (1999) In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother 43:1406-1411 (Pubitemid 29259334)
24. Saballs M, Pujol M, Tubau F et al (2006) Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 58:697-700 (Pubitemid 44288144)
25. Drusano GL (2005) Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics. Pharmacotherapy 25:150S-158S (Pubitemid 41790090)
26. Bamberger DM, Foxworth JW, Bridwell DL, Shain CS, Gerding DN (2005) Extravascular antimicrobial distribution and the respective blood and urine concentrations in humans. In: Lorian V (ed) Antibiotics in laboratory medicine, 5th edn. Lippincott Williams & Wilkins, Philadelphia, PA, pp 719-814
27. Prokesch RC, Hand WL (1982) Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother 21:373-380 (Pubitemid 12117777)
28. Ziglam HM, Baldwin DR, Daniels I et al (2002) Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 50:1011-1015 (Pubitemid 36032825)
29. Barcia-Macay M, Seral C, Mingeot-Leclercq MP et al (2006) Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 50:841-851 (Pubitemid 43327786)
30. Inderlied CB, Nash KA (2005) Antimycobacterial agents: in vitro susceptibility testing, spectra of activity, mechanisms of action and resistance, and assays for activity in biologic fluids. In: Lorian V (ed) Antibiotics in laboratory medicine. Lippincott Williams & Wilkins, Philadelphia, PA, pp 155-225
31. Weber A, Opheim KE, Smith AL et al (1983) High-pressure liquid chromatographic quantitation of rifampin and its two major metabolites in urine and serum. Rev Infect Dis 5:S433-S439